

CURRICULUM VITAE

ANIRBAN BASU

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute
Department of Pharmacy, School of Pharmacy, University of Washington
1959 NE Pacific St, Magnuson Health Sciences Center, Room H-375Q, Box 357630, Seattle, WA, 98195-7630
Email: basua@uw.edu Tel: (206) 616-2986 Fax: (206) 543-3964
Web: <http://faculty.washington.edu/basua>

CITIZENSHIP: USA

CAREER BIO

Anirban Basu's (Ph.D. Public Policy (Health Economics), University of Chicago; MS Biostatistics, UNC-Chapel Hill) work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost-effectiveness analyses, causal inference methods, program evaluation, and outcomes research. He is regarded as a leading international expert on methods to study heterogeneity in clinical and economic outcomes, micro behavior with respect to heterogeneous information, and to establish the realized and potential values of medical technologies and public health interventions and individualized care. Dr. Basu is an Associate Editor for *Observational Studies* and formerly of the *Journal of Health Economics* and *Health Economics*. He has taught courses in health economics, decision analysis, cost-effectiveness analysis and health services research methods. He served on the Second Panel on Cost-effectiveness Analysis in Health and Medicine. Currently, Dr. Basu is the Stergachis Family Endowed Professor and Director of The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington Seattle. He holds joint appointments with the Departments of Health Services and Economics at UW, is a Faculty Research Fellow at the National Bureau of Economic Research, and an elected Fellow of the American Statistical Association.

EDUCATION

B.S., Pharmaceutical Technology, Jadavpur University, India, (1995).
M.S., Pharmaceutical Sciences, University of Toledo, (1997).
M.S., Biostatistics, University of North Carolina, Chapel Hill (1999).
Ph.D., Public Policy (Health Economics), University of Chicago, (2004).
Dissertation: *Three essays in medical cost-effectiveness analysis.*

PROFESSIONAL EXPERIENCE

RESEARCH ASSOCIATE (Intern), Statistics Collaborative Inc., Washington DC (1997).
RESEARCH ASSISTANT (Student), Collaborative Studies Coordinating Center, UNC-CH (1997-1999).
CONSULTANT (Intern), Dept. of Statistics, Abbott Laboratories Inc., Abbott Park, IL (1999).
RESEARCH ASSISTANT (Student), National Opinion Research Center, University of Chicago, IL (2000).
INSTRUCTOR, Section of General Internal Medicine, Department of Medicine, University of Chicago, IL (2004-2006).
PROJECT ANALYST, Decision and Information Sciences, Argonne National Laboratory, IL (2004-2006).
MEMBER, Clinical Cancer Genetics and Prevention Program at the University of Chicago Cancer Center, Chicago, IL (2006-2010).
ASSISTANT PROFESSOR, Department of Medicine, University of Chicago, IL.
Section of General Internal Medicine (2006 - 2008).
Section of Hospital Medicine (2008 - 2010)
AFFILIATE, Center for Health and the Social Sciences, University of Chicago, Chicago, IL (2005-).
EXTERNAL AFFILIATE, Health Econometrics and Data Group, The University of York, UK (2007-).
FACULTY RESEARCH FELLOW, National Bureau of Economic Research, Cambridge, MA (2008-).
EXTERNAL AFFILIATE, Center for Health and the Social Sciences, University of Chicago, Chicago, IL (2011-).
AFFILIATE INVESTIGATOR, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, WA, (2011-)
ASSOCIATE PROFESSOR, University of Washington, Seattle (2011 -)
Department of Health Services, School of Public Health

(ADJUNCT) Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy
(ADJUNCT) Department of Economics (2012 -)
PROFESSOR, University of Washington, Seattle (2014 - 2015)
Department of Health Services, School of Public Health
(ADJUNCT) Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy
(ADJUNCT) Department of Economics
Co-DIRECTOR, Program in Health Economics and Outcomes Methodology (PHEOM), Dept. of Health Services, UW (2012-)
STERGACHIS FAMILY ENDOWED PROFESSOR, University of Washington, Seattle (2015 -)
(DIRECTOR) Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy (2015-2017)
(DIRECTOR) The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute (2017 -)
(JOINT) Department of Health Services, School of Public Health
(ADJUNCT) Department of Economics

AWARDS & HONORS

Diploma in Computer Programming and Applications from National Computing Center, UK with DISTINCTION award (1993).
First Class Honors in Bachelors Degree in Pharmaceutical Sciences (1995).
Outstanding Academic Performance, Rho Chi Society, University of Toledo, OH (1996).
Irving Harris Fellowship Award from the School of Public Policy, University of Chicago (1999-2004).
Winner of Student Paper competition, Health Policy Statistics Section for the 2003 Joint Statistical Meetings (2003).
Winner of Student Travel Award, International Conference Health Policy Research (2003).
Wodecroft Young Investigator Award, National Alliance for Research of Schizophrenia and Depression (NARSAD) (2005).
Research Excellence Award for Methodological Excellence, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2007).
Alan Williams Health Economics Fellowship, University of York, UK (2008).
ISPOR Bernie O'Brien New Investigator Award, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2009).
2009 Labelle Lecturer in Health Services Research, McMaster University, Canada (2009).
Society for Medical Decision Making Comparative Effectiveness Research Essay Contest Winner (2009).
Research Excellence Award for Methodological Excellence, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2016).
Fellow, American Statistical Association (2016-).
Mid-Career Excellence Award, Health Policy Statistics Section, American Statistical Association (2018).

TEACHING EXPERIENCE

TEACHING ASSISTANT, College of Pharmacy, University of Toledo, Toledo, OH (1995-1997).
TEACHING ASSISTANT, Department of Biostatistics, University of North Carolina at Chapel Hill, NC (1998).
TEACHING ASSISTANT, Harris School of Public Policy Studies, University of Chicago, IL (2000-2003).
GRADUATE ASSISTANT, University of Chicago, IL (2000-2004).
STATISTICAL CONSULTANT AND MENTOR to many faculties, research scholars and medical students in the Department of Medicine (4 hours/week) (2004-)
INVITED LECTURER, Global Health Economics, Amgen Inc., Thousand Oaks, CA (2009)
Methods to adjust for hidden bias in observational research using instrumental variables (1-day course)
INVITED LECTURER, Department of Economics, National University of Ireland, Galway (2010)
Medical Decision Analysis and Cost-effectiveness Analysis (5-day course to Masters and PhD students)
ANNUAL MEETING FACULTY, Society for Hospital Medicine Annual Meeting (2010)
Comparative Effectiveness and Cost-effectiveness Research (90-minute session, with David Meltzer)
LECTURER, University of Chicago, IL (2007- 2011)
Advanced Applications of Cost-Effectiveness Analysis in Health (Public Policy 44800), Spring 2007 (with David Meltzer). Teach five 3 hour sessions.
Applied Medical Cost-Effectiveness Analysis (Public Policy 46000) Winter 2008-2010 (with William Dale, Elbert Huang, David Meltzer & Harold Pollack). Teach two 3 hour sessions.

Advanced Methods for Comparative Effectiveness Research (Public Policy 44800) Spring 2010 & 2011 (with David Meltzer). Teach eight 3 hour sessions.

INVITED LECTURE, U.S. Food and Drug Administration, Silver Spring, MD (2011)

Comparative effectiveness research: Introduction and Methods (1-day course)

INVITED LECTURE, Merck, White House Station, NJ (2014)

Use of instrumental variable methods in comparative effectiveness research (1-day course)

INVITED LECTURE, University of Lausanne, Switzerland (2016)

Cost-effectiveness Analysis and Health Technology Assessment (3-day course)

INVITED LECTURE, Healthcare Technology Assessment Fellowship, WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, National Health Systems Resource Centre, Ministry of Health & Family Welfare, Govt. of India (2017-2018)

Cost-effectiveness Analysis and Health Technology Assessment (3-day course)

LECTURES, University of Washington, WA (2011-)

Welfare Economics foundations for cost-effectiveness analysis (HSERV 583, '11 & '12) – 1.5 hour sessions

Understanding the role of uncertainty in decision models (HSERV 583, '13 & '14) – 1.5 hour sessions

Quantitative methods for valuing information in health care (HSERV 584, '11) – 1.5 hour sessions

Introduction to comparative effectiveness methods (HSERV 523, '11; HSERV 513 & HSERV 592, '12) – 1.5 hour sessions

Instrumental variable methods (HSERV 523, '11) – 1.5 hour session

Financing healthcare (HuBio 555, '13, '14) – 1.5 hour session to 250 2nd year medical students

Quantile regression methods (HSERV 525, '11, HSERV 523, '12) – 1.5 hour sessions

Variations in healthcare spending: Observations & Implications (PHARM 568, '14 -'16) – 1.5 hour sessions

Causal inference in observational studies (HSERV 525), Spring 2013 -2017- Ten 3 hour sessions.

ADVISING

THESIS CHAIR OR COMMITTEE MEMBER

<u>Name</u>	<u>Program</u>	<u>Served as</u>	<u>Initial Placement</u>
Jennifer Humensky	PhD, 2003-2009, University of Chicago, School of Public Policy Studies	PhD Committee Member	Research Director, NYS Center of Excellence for Cultural Competence, New York State Psychiatric Institute
Anjali Oza	PhD, 2009-2010, University of Chicago, School of Public Policy Studies	PhD Committee Member	Associate, Analysis Group
Vasanthi S. Gowri, MD	eMPH, 2011, University of Washington, Department of Health Services	eMPH Committee Member	Hospitalist, Swedish Medical Center, Edmunds WA
Joelle Abramowitz	PhD, 2011-Present, University of Washington, Department of Economics	PhD Committee Member	Researcher, US Census Bureau
Justin Robertson	PhD, 2012-Present, University of Washington, Department of Economics	PhD Committee Member	Acting Assistant Professor, Dept. of Health Services, University of Washington
John Dickerson	PhD, 2012-2014, University of Washington, Department of Health Services	PhD Committee Chair	Investigator, Center for Health Research, Kaiser Permanente Research
Megan Shepherd-	PhD, 2012-2015, University	PhD Committee	Post-doc, VA HSR&D Durham.

Banigan	of Washington, Department of Health Services	Member	
Caroline Bennette	PhD, 2012-2014, University of Washington, PORPP	PhD Committee Member	AHRQ K12 Post-Doc, Group Health Research Institute
Wei-Jhih Wang	MS, 2013-2015, University of Washington, Department of Health Services PhD, 2015- Present The CHOICE Institute	MS Committee Chair	PhD Student, PORPP, University of Washington
Preeti S. Bajaj	PhD, 2012-Present, University of Washington, PORPP	PhD Committee Member	Genentech Inc.
Kai Yeung	PhD, 2013-Present, University of Washington, PORPP	PhD Committee Member	Assistant Investigator, Group Health Research Institute
David D Kim	PhD, 2012-Present, University of Washington, Department of Health Services	PhD Committee Chair	Assistant Professor, Tufts Medical Center
Sarah Beth Barnett	PhD, 2012-Present, University of Washington, Department of Health Services	PhD Committee Member	Post-doctoral Fellow, University of California, Berkeley
Sungchul Park	PhD, 2013-Present, University of Washington, Department of Health Services	PhD Committee Chair	
Benjamin Ely	PhD, 2012-Present, University of Washington, Department of Health Services	PhD Committee Chair	Performance Engineer, Amazon Inc.
Solomon Lubinga	PhD, 2014-2017, University of Washington, PORPP	PhD Committee Chair	Post-doctoral Fellow, PORPP, UW
Mark Bouthavong	PhD, 2016-Present, University of Washington, The CHOICE Institute	PhD Committee Member	
Meng Li	PhD, 2016-Present, University of Washington, The CHOICE Institute	PhD Committee Member	
Devender Dhandha	PhD, 2016-Present, University of Washington, The CHOICE Institute	PhD Committee Member	
Jordan Banks	PhD, 2017-Present, University of Washington, Health Services	PhD Committee Chair	

MENTORING

Lisa Shah M.D. (2006-2010, University of Chicago). (Presently: Assistant Professor, Johns Hopkins University)

Jing Guo, Doctoral Student (2009 - 2010, University of Chicago) (Presently: Economist, American Institutes for Research)
Julia Slejko, Ph.D. (2012-2014, Pfizer-PORPP Post-doc, University of Washington). (Presently: Assistant Professor, University of Maryland)
Amber Sabbatini MD (2014 - CER-K12 Scholar, Acting Assistant Professor, University of Washington).
Souvik Banerjee PhD (2015- 2016, Pfizer-PORPP Post-Doc, University of Washington) (Presently: Research Assistant Professor, Boston University)
Ashok Reddy MD (2016 - Assistant Professor, Medicine, University of Washington)
Alice Ellyson PhD (2016 - , Pfizer-PORPP Post-Doc, University of Washington)
Jevay Grooms PhD (2016 - , Post-doctoral Fellow, University of Washington)
Liisa Laine PhD (2017 - , Senior Fellow, University of Washington)
Lindsay White PhD (2017 - , Post-doctoral Fellow, University of Washington)

EDITORIAL ACTIVITIES

ASSOCIATE EDITOR, *Observational Studies* (2014-)

ASSOCIATE EDITOR, *Health Economics* (2009-2016)

ASSOCIATE EDITOR, *Journal of Health Economics* (2008- 2015)

SECTION CO-EDITOR. *Health Econometrics*, Encyclopedia of Health Economics (ed. Tony Cuyler, Elsevier) (2010 - 2013)

SECTION CO-EDITOR. *Economic Evaluation*, Encyclopedia of Health Economics (ed. Tony Cuyler, Elsevier) (2010 - 2013)

REVIEWER (2003-) for

Applied Economics: *Journal of Health Economics*, *Health Economics*, *Journal of Mental Health Policy and Economics*, *PharmacoEconomics*

Statistics: *Statistics in Medicine*, *Journal of the Royal Statistical Society- Series B*, *Health Services and Outcomes Research Methodology*, *Operations Research*

Health Services Research: *Medical Decision Making*, *Value in Health*, *Pharmacoepidemiology and Drug Safety*, *Health Services Research*

Clinical: *Stroke*, *Journal of Clinical Psychopharmacology*, *Stroke*, *Journal of the National Cancer Institute*

Grants: National Science Foundation, Research Grants Council (RGC) of Hong Kong, National Institute of Health (NIH)

PROFESSIONAL AFFILIATIONS

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

American Statistical Association (ASA)

International Health Economics Association (iHEA)

American Society of Health Economists (ASHE)

Society for Medical Decision Making (SMDM)

American Economic Association (AEA)

PROFESSIONAL SERVICE

Health Policy Statistics Section, American Statistical Association (<http://www.amstat-online.org/sections/hpss/info.htm>)

Member, International Conference for Health Policy Research (ICHPR) Scientific Planning Committee, Boston, MA (2005).

Program Chair-Elect (2007).

Program Chair (2008).

Member, International Conference for Health Policy Statistics (ICHPS), Scientific Planning Committee, Philadelphia, PA (2008).

Conference Co-Chair, International Conference for Health Policy Statistics (ICHPS), Washington DC (2010).

Conference Advisory Board, International Conference for Health Policy Statistics (ICHPS) (2011, 2013 and 2015)

Society for Medical Decision Making (www.smdm.org)

Member, Nominations Committee (2008).

Co-Chair, Scientific Committee for Annual Meeting (2009).

Co-Chair, Scientific Committee for Annual Meeting (2010).

Trustee (Elected) (2010-2013).

Annual Conference Co-Chair, Chicago IL (2011).
 Inaugural Asia-SMDM Meeting Co-Chair, Singapore (2013)
 Annual Health Econometrics Workshop (www.healtheconometrics.org)
 Founding Member and the Chair of Inaugural Conference, Chicago, IL (2009)
 Member, Organizing Committee (Annually from 2009 onwards).

Others

Member, American Society of Health Economist (ASHE) Scientific Committee (2005-2007).
 Committee Member, Behavioral Health Theme, Annual Research Meeting, Academy Health (2008).
 Program Committee Member, The 14th NIMH Biennial Research Conference on the Economics of Mental Health: Toward Building a High Performance Mental Health System (2008).
 Member of Technical Panel for Johns Hopkins University Evidence-Based Practice Center Project: *Evaluating Economic Outcomes in Systematic Reviews* (2008-2010).
 Committee Member, Comparative Effectiveness Research Theme, Annual Research Meeting, Academy Health (2010 & 2011)
 Chair, AHRQ Comparative Effectiveness Research Special Interest Group (2010).
 Steering Committee Member. Chicago-Area Decide-2 Network Center. (2010-).
 Member, NHLBI Value of Information Working Group (2010).
 Scientific Planning Committee Member, DEClDE Methods Symposium (2012).
 Chair, Research Committee, Department of Health Services, UW (2012 - 2015).
 Scientific Planning Committee, IOM-PCORI Symposium on Observational Data Methods, Institute of Medicine (2013).
 Scientific Planning Committee, IOM Workshop on Standards for Benefit-Cost Analysis of Preventive Interventions for Children, Youth, and Families (2013).
 Member, Second Panel on Cost-effectiveness Analysis in Health and Medicine (<http://2ndcep.hsrb.ucsd.edu/>) (2013-2016)
 Advising Member on Health Insurance Commission for Hon'ble Health Minister, Govt. of Andhra Pradesh, India (2017 -)
 ISPOR Task Force member, Value of Information Analysis for Research Decisions. <https://www.ispor.org/TaskForces/Value-of-Information-Analysis-for-Research-Decisions.asp> (2016 -)

CURRENT RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
Empowering the Annual Health Econometrics Workshop	Principal Investigator	R13HS025609 (AHRQ)	09/08/2017 - 08/31/2020	\$105,000
Personalized Medicine Economics Research (PriMER)	Co-Investigator PI: Veenstra (UW, PORPP)	U01 AG 047109, NIH	9/30/2013 – 6/30/2018	\$1,957,349
Value of information methods for NHLBI trials	Principal Investigator	R01HL126804, NHLBI	04/15/2015 – 03/31/2019	\$2,709,334
Effectiveness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular Disease	Sub-PI PI: Coleman, Kaiser Permanente	R01, NIH	7/1/2016 – 4/30/2020	\$1,044,478

PENDING RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
Personalized Risk-Adaptive surveillance Strategies in canCEr (PRAISE)	Co-Investigator PI: Bansal (UW, PORPP)	R01, NIH		

PAST RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
A structured approach to prioritizing cancer research using stakeholders and value of information	Co-Investigator PI: Ramsey (Fred Hutch)	PCORI	10/1/2013 - 03/31/2017	
Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies	Sub-PI PI: Huang (U of Chicago)	R01; (AHRQ)	7/1/2012- 6/30/2016	\$297,006
Innovative methods for modeling longitudinal medical costs	Sub-PI PI: Liu (Northwestern)	R01 HS020263 (AHRQ)	01/01/2012 - 08/31/2016	168,872
Instrumental Variable Methods for Censored Cost Data and an Application in Prostate Cancer	Principal Investigator	R01 CA155329 (NIH-NCI)	7/1/2011- 6/30/2014	\$1,613,190
Empowering the Annual Health Econometrics Workshop	Principal Investigator	R13 HS021019 R13 HS 023030 (AHRQ)	01/01/2012 - 2/2/2017	72,000
Advancing Instrumental Variable Methods in Comparative Effectiveness Research	Principal Investigator	RC4 CA155809 (NIH-NCI)	9/28/2010- 8/31/2013	\$1,472,354
A comprehensive probabilistic micro-simulation model for cost-effectiveness analysis of pharmacological treatment algorithms in schizophrenia	Principal Investigator	R01 MH083706 (NIH-NIMH)	09/01/2008 - 08/30/2013	\$1,970,439
Monoclonal Antibodies in Cancer Care: Is Underinsurance an Access Barrier	Co-Investigator PI: Shih (U of Chicago)	R01 HS18535-01 (AHRQ)	09/01/2009 - 08/31/2013	313,612
Self-Selection in Prostate Cancer Treatments	Co-Investigator PI: Meltzer (UofC)	Pfizer Cost-effectiveness Grant	04/01/2007- 12/1/2009	\$89,489
Causal Estimation of the Intention-To-Treat Treatment Effect in Randomized Trials	Principal Investigator	Center for Health Administration Studies (CHAS) Seed Grant	07/01/05 – 06/30/06	\$7,500
Measuring spillover effects of prostate cancer patients' health on their partners	Principal Investigator	UofC, Cancer Research Center, Cancer and Social Sciences Pilot Project	03/01/05 - 6/30/07	\$20,000
Model for cost-effectiveness analysis of the REACH-OUT Chicago Children's Diabetes Prevention Project	Principal Investigator	U Chicago, Pilot Grant Award	03/01/05 - 02/28/06	\$18,608
Estimating risks and costs of cardiovascular diseases associated with the long-term use of atypical antipsychotics in schizophrenia	Principal Investigator	NARSAD Young Investigator Award	07/01/05 – 06/30/08	\$60,000
Measuring the effects of patient's health on family members' quality of life and incorporating them in cost-effectiveness analysis	Principal Investigator	Pfizer Cost-effectiveness Grant	01/01/06 – 12/31/07	\$60,000
Quality-of-life and willingness-to-pay for clinical symptoms and social outcomes of patients with	Principal Investigator	University of Chicago CCEHPE	07/01/07 – 06/30/08	\$22,000

schizophrenia		Pilot Grant		
REACH-OUT Chicago Children's Diabetes Prevention Project	Co-Investigator PI: Burnet (UofC)	R01, NIDDK(NIH) 1 R18 DK62991-01A2	9/30/04 - 6/30/09	\$2,049,866
Artificial Pancreas Project Health Economics Follow-On Study	Co-Investigator PI: O'Grady (NORC)	Juvenile Diabetes Research Foundation 22-2006-1126	9/01/06 - 8/31/09	\$459,388

INVITED LECTURES AND PROFESSIONAL PRESENTATIONS

Topics:

Promise of real-world data
 Towards a hedonic value framework in healthcare
 Public policies around "real" big data.
 Real-world Progression in Diabetes (RAPIDS) model.
 Price elasticities of pharmaceutical under a value-based formulary setting.
 2SLS versus 2SRI: Appropriate methods for rare outcomes and/or rare exposures.
 Selecting into and out of selection: Long-term health impacts of alternative systems of education
 Prostatectomy versus Watchful Waiting among elderly patients with clinically localized Prostate Cancer: Exploring heterogeneity in survival effects
 Long-Term Health Returns to Alternative School Systems: Evidence from UK
 Identifying effect heterogeneity using instrumental variables
 Cost-effective decision making in health care: Myth or reality
 Heterogeneity in CER: the case of schizophrenia treatments in Medicaid
 A framework for prioritizing precision medicine
 Personalized Medicine and Economic Evaluations.
 Should everyone follow results from large effectiveness trials?
 Valuing information in health.
 Aligning information with decision-making.
 Estimating decision-relevant comparative effects using instrumental variables.
 Intensive versus extensive margins in comparative effectiveness research.
 Economics and econometrics of individualization in comparative effectiveness research.
 Regression estimators for quality of life and quality-adjusted life years.
 Economics of risk stratification.
 Use of decision models in the regulation of medical devices.
 Using instrumental variable analyses to inform policy.
 Modeling healthcare expenditures.
 Estimating lifetime or episode-of-illness costs under censoring.
 Individualizing comparative effectiveness research for diagnostic imaging.
 The impact of comparative effectiveness research on health and health care spending.
 Welfare consequences of comparative effectiveness research.
 Tragedy of averages in comparative effectiveness research: The case for antipsychotics and diabetes.
 Comparative effectiveness research: Another emperor with no clothes?
 Comparative effectiveness research in prostate cancer: building the blocks.
 Antipsychotics and diabetes in schizophrenia: Did comparative effectiveness research make a difference?
 Antipsychotics-induced economic burden of diabetes in schizophrenia.
 Economic incentives to invest in comparative effectiveness research using Bayesian adaptive trials.
 The impact of the Medicare Part D prescription benefit on drug utilization and expenditures: the case for dual-eligibles.
 Use of propensity scores in non-linear response models.

A time trade-off method to elicit preferences of spouses about the influence of their husbands' potential prostate cancer health states on them.

Understanding assumptions behind propensity scores versus instrumental variable estimators: how do we interpret estimates of incremental costs?

Risk prediction index for new onset major depression in the national longitudinal study of adolescent health.

A simple linear function to predict joint state utilities from single state utilities in prostate cancer.

Use of instrumental variables in the presence of heterogeneity and self-selection: An application in breast cancer patients.

Spillover effects of health on family members: Theoretical and measurement issues.

Risk adjustment with flexible link and variance function models.

Impact of heart failure on 1-year costs after myocardial infarction related hospitalization: an application using a flexible link and variance function model.

Comparing alternative models: log vs Cox proportional hazard.

Estimating marginal and incremental effects on health outcomes using flexible link and variance function parameters.

Family perspective in economic evaluation of medical technology (Alternative title Friends, families and cost-effectiveness analysis).

Modeling costs with generalized gamma regressions.

Hierarchical Linear Models.

Venues: Intramural

University of Chicago, Chicago IL:

Demography Workshop, October 2002.

Health Studies Seminar Series, April 2003, January 2008, November 2008.

Center for Health Administration (CHAS) Workshop, November 2003.

Health Economics Workshop, June 2001, October 2003, March 2005, June 2006, January 2010.

Research in Progress, General Internal Medicine, March 2004, March 2006.

Operations Research and Management, Booth School of Business, October 2010.

University of Washington, Seattle WA:

PORPP Graduate Seminar, January 2011, November 2011.

CHASE Work-in-Progress Session, March 2011, October 2012.

Department of Psychiatry Research Seminar, October 2011.

Institute of Health Metrics and Evaluation (IHME), December 2011.

Department of Economics, April 2012.

Department of Pharmacy, Corporate Advisory Board Meeting, September 2012.

Center for Statistics and the Social Sciences (CSSS) Seminar Series, February 2012, October 2013, January 2015

PHEnOM Seminar, March 2013, March 2015, March 2016.

Prostate SPOR, March 2015

CHASE Seminar, October 2016.

PORPP PhD Seminar, October 2017.

Venues: National

2002

Invited Speaker, American Public Health Association Annual Meeting. Philadelphia, November.

2003

International Biometric Society (ENAR) Spring Meeting, Tampa, April.

International Health Economics Association (iHEA) Bi-annual Congress. San Francisco, June.

Tools and Methods for Designing, Performing, and Reporting Primary Care Research Based Practice Networks Research.

Sponsored session by The Agency for Healthcare Research and Quality. Washington DC, July.

Joint Statistical Meeting , Health Policy Statistics Section, San Francisco, August.

Society for Medical Decision Making (SMDM) Annual Meeting. Chicago, October.

International Conference on Health Policy Research, Chicago, October.

2004

Department of Health Policy and Administration, Yale University, May.

Keynote Speaker, Third Annual Advanced Research Methods Symposium, Center for Disease Control, May.

Society for Medical Decision Making, Annual Meeting, October.

2005

Department of Health Care Policy, Harvard Medical School, January.

Invited Speaker, International Conference on Health Policy Research (iHEA) Bi-annual Meeting. Boston, October.

Center for Pharmacoeconomics Research, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, August.

2006

American Society for Health Economists (ASHE) Inaugural Meeting. Madison WI, June.

Health Economics Brown Bag Seminar Series, Department of Economics, University of Illinois at Chicago, Chicago. September.

Society for Medical Decision Making, Annual Meeting, October.

2007

Academy Health, Annual Research Meeting, June.

Society for Medical Decision Making, Annual Meeting, October.

2008

Invited Speaker, International Conference for Health Policy Statistics (ICHPS), Philadelphia, January.

Center for Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, Northwestern University, March.

2nd Biennial Conference of the American Society of Health Economists. Duke NC, June.

Amgen Alternative Estimators for Unbiased Treatment Effects Advisory Board, July.

Invited Speaker, Society for Medical Decision Making, Annual Meeting, October.

Invited Speaker, Society for Judgment and Decision Making, Annual Meeting, November.

2009

Invited Speaker, International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting, May.

20th NIMH Conference on Mental Health Services Research (MHSR), Washington DC, July.

Invited Speaker, Grand Rounds, Department of Psychiatry, Vanderbilt University, June.

Invited Speaker, Specialized Programs of Research Excellence (SPORE) in prostate cancer, Northwestern University, September.

The 31st Annual Meeting of the Society for Medical Decision Making, Hollywood CA, October.

20th Annual Health Economics Conference, Boston MA, October.

Invited Speaker, Rice/University of Houston Empirical Seminar Series, October.

2010

Invited Panelist, RSNA/NIBIB Workshop on Comparative Effectiveness Research (CER) for Diagnostic Imaging, Chicago IL, April.

3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June.

Invited Speaker, Academy Health Annual Research Meeting, Boston, MA, June.

Invited Speaker, Health Economics Resource Center Cyber Seminar, USVA, June.

Invited Panelist, *Responding to the National CER Agenda: Evolving Data Sources and Analytics*, Lewin Center for Comparative Effectiveness Research, Washington DC, June.

Invited Speaker, Department of Health Services Research, School of Public Health, University of Washington, WA, August.

Invited Speaker, Workshop sponsored by FDA/Center for Devices and Radiological Health, August.

Invited Speaker, Pfizer Statistics Group, New York, October.

2011

Invited Speaker, Fourth Annual Bayesian Biostatistics Conference, University of Texas-MD Anderson, Houston, January.

Invited Panelist, 7th Annual Scientific Meeting, The International Society for CNS Clinical Trial and Methodology, Washington DC, February.

Invited Speaker, The Robert Wood Johnson Foundation Physician Faculty Scholars Program (RWJF PFSP), Conference on Comparative Effectiveness Research, Stanford University, CA, February.

Invited Speaker, Institute of Clinical and Translational Sciences CER Seminar, University of Iowa, March.

Invited Plenary Speaker, Western Pharmacoeconomics Conference, University of Washington, April.

Invited Speaker, Academy Health Annual Research Meeting, Seattle, WA, June.

Invited Speaker, Joint Statistical Meetings, Miami, FL, August.

Invited Speaker, Mayo Clinic, Rochester MN, September.

2012

Invited Speaker, AHRQ-SMDM Research Seminar Series, February.

Invited Speaker, DIA-NPC Symposium on Comparative Effectiveness: A Real-World User's Guide, March.
4th Biennial Conference of the American Society of Health Economists. Twin Cities, MN, June.

Invited Speaker, Triangle Health Economics Workshop, University of North Carolina Chapel Hill, September.
4th Annual Health Econometrics Workshop (AHEW), New York City, NY, September.

2013

Invited Speaker, IOM-PCORI Symposium on Observational Studies in a learning Health System, Washington DC, April.

Invited Speaker, Department of Health Studies, University of Chicago, IL, May.

ISPOR 18th Annual International Meeting, New Orleans LA, May.

Invited Speaker, IOM Workshop on Standards for Benefit-Cost Analysis of Preventive Interventions for Children, Youth, and Families, Washington DC, November.

2014

Invited Speaker, Diabetes Modeling Masterclass, The Mount Hood 2014 Challenge. San Francisco, June.

2015

Invited Speaker, Leonard Davis Institute of Health Economics, University of Pennsylvania, PA, February.

Invited Speaker, Starr Lectureship in Biostatistics, Brown University, RI, March.

Society for Medical Decision Making Annual Meeting, St. Louis, October.

Joint Annual Health Econometrics Workshop and Australasian Workshop on Econometrics and Health Economics, Honolulu, December.

2016

Invited Panelist, Phacilitate Cell and Gene Therapy Conference, Washington DC, January

Invited Speaker, Will Manning Memorial Symposium, University of Chicago, Chicago, March.

ISPOR 21st Annual International Meeting, Washington DC, May.

6th Biennial Conference of the American Society of Health Economists. Philadelphia, PA, June.

Panel Speaker, Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine National Academy of Sciences, Washington DC, December.

2017

Invited Panelist, Panel on Optimizing Use of 'Big Data' for Patient Identification and Disease Management: Separating Signal from Noise, The International Society for CNS Clinical Trials and Methodology Annual Meeting, Washington DC, February.

Invited Speaker & Panelist, ISPOR 22st Annual International Meeting, Boston, MA, May.

Invited Panelist, NIH Symposium – Turning Discovery into Health: The Contributions of Economic Research, Washington DC, September.

Invited Panelist, Society for Medical Decision Making Annual Meeting, Pittsburgh, October.

2018

Invited Speaker, The Fourth Annual Global Health Economics Colloquium: The Economics of Non-Communicable Diseases. UCSF Mission Bay, February.

Venues: International

2005

International Health Economics Association (iHEA) Bi-annual Congress. Organized session on Health Econometrics for Cost and Utilization Data. Barcelona, July.

2007

International Health Economics Association (iHEA) Bi-annual Congress. Copenhagen, July.

2008

CHE-TEEHTA Seminar, University of York, York UK, May.

Section of Public Health and Health Policy, University of Glasgow, UK, May.

HEDG Group, University of York, York, UK, May.

17th European Workshop of Econometrics and Health Economics, Coimbra, Portugal, September.

2009

18th European Workshop of Econometrics and Health Economics, Cagliari, Italy, September.

Invited Speaker, 2009 Labelle Lecture, McMaster University, Canada, October.

2010

2010 Joint Statistical Meetings, Vancouver, Canada, August.

2011

Invited Speaker, The Second International Symposium on Biopharmaceutical Statistics, Berlin, Germany.

International Health Economics Association (iHEA) Bi-annual Congress. Toronto, Canada, July.

20th European Workshop of Econometrics and Health Economics, Cagliari, York, UK, September.

2012

Invited Delegate, National Seminar on 'Economic and Social impact of Cancer in India', Cancer Foundation of India, Kolkata, India. January.

Invited Speaker, Personalised Medicine in Canada: A Multi-Stakeholder Workshop to Examine the Canadian Perspective, Ottawa, CA, January.

Invited Speaker, Third Australasian Workshop on Econometrics and Health Economics, Sydney NSW, Australia. April.

Invited Plenary Speaker, Vancouver Health Economics Meeting, Vancouver, BC Canada. July.

2013

Invited Key-note speaker, Healthcare Leadership College, Singapore Ministry of Health Holdings Ltd, Singapore, January.

Invited Speaker, Pfizer Pharmaceutical Economics Conference, Rio de Janeiro, Brazil, March.

Invited Speaker, Inaugural Economics of Cancer research Symposium, Galway, Ireland, September.

Invited Speaker, Department of Economics, National University of Ireland, Galway, Ireland, September

2014

Panel Speaker, International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting, Montreal, Canada, June.

10th World Congress in Health Economics, Dublin, Ireland, July.

Invited Speaker, Institute for Health Policy, Management and Evaluation, University of Toronto, Canada, September.

2015

International Health Economics Association (iHEA) Bi-annual Congress. Milan, Italy, July.

Invited Speaker, Chung-Ang University, South Korea, October.

2016

Invited Speaker, Institut Universitaire de Médecine Sociale et Préventive, Lausanne, Switzerland, July.

Panel Speaker, Society for Medical Decision Making Annual Meeting, Vancouver BC, October.

ISPOR 20th Annual European Congress, Vienna, Austria, November.

2017

ISPOR 21th Annual European Congress, Glasgow, Scotland, November.

Discussant for:

- Use of Bayesian Net Benefit regression to update cost-effectiveness analysis.* The 13th NIMH Biennial Research Conference on the Economics of Mental Health. Washington DC, September 2006.
- Budget constraints in expected utility analysis.* 2nd Biennial Conference of the American Society of Health Economists. Duke NC, June 2008.
- Health utility crosswalks: a Bayesian Beta regression approach.* 3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June 2010
- Using Medicare for Comparative Effectiveness Research.* 3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June 2010
- Accounting for Heterogeneity in Treatment Selection: The Case of Revascularization.* 3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June 2010
- Adverse Selection, Moral Hazard and the Demand for Medigap Insurance.* Nineteenth European Workshop on Econometrics and Health Economics, September 2010.
- Effects of Eating Disorder Parity Laws on Adolescent Health Behaviors.* The 15th Biennial Research Conference on the Economics of Mental Health: Comparative Effectiveness and Mental Health Care Financing, September, 2010
- Empirical Comparative Effectiveness Research: Data, Statistical Analysis, and the Evidence Base of Evidence-based Healthcare.* International Health Economics Association (iHEA) Bi-annual Congress. Toronto, Canada, July, 2011.
- The Role of the Expected Value of Individualized Care in Cost-effectiveness Analysis and Decision Making.* International Health Economics Association (iHEA) Bi-annual Congress. Toronto, Canada, July, 2011.
- Resource use trajectories for aged Medicare beneficiaries with complex coronary conditions.* 4th Biennial Conference of the American Society of Health Economists. Twin Cities, MN, June, 2012.
- Difference in differences for stayers and movers with time-varying qualification.* Twenty-second European Workshop on Econometrics and Health Economics, September 2013.
- Parameter Uncertainty, Heterogeneity, and Value of Information: a Combined Analytical Approach.* Third Van-HEM Meeting, June 2015.

PUBLICATIONS (book chapters)

1. Polsky D, **Basu A.** *Selection bias in observational data.* In Elgar Companion to Health Economics. Ed. Jones A., Chap 43: 455 – 465, Edward Elgar Publishing Inc., UK, 2006. (2nd. edition, forthcoming 2012)
2. **Basu A,** Lehman A. *Decision Analytic Techniques.* In Difficult Decisions in Thoracic Surgery - An Evidence-Based Approach. Ed. Ferguson M., Springer, NY, 2007. (2nd. Edition in 2011)
3. Meltzer D, **Basu A,** and Conti R. *The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives.* Draft manuscript prepared at the request of the IOM Roundtable on Evidence-Based Medicine, University of Chicago, 2007.
4. Espinoza MA, Sculpher MJ, Manca A, **Basu A.** *Analysing heterogeneity to support decision making.* In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1:Elsevier; 2014. pp.71-76.2014.
5. **Basu A,** Mullahy J. *Health Econometrics: An overview.* In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1:Elsevier; 2014.
6. **Basu A.** *Individualization in comparative effectiveness research.* In: Handbook of Health Services Research. (ed. Adrian Levy and Boris Sobolev, Springer) Pg 255-274, 2016.
7. Meltzer D, **Basu A,** Sculpher M. *Theoretical foundations in cost-effectiveness analysis.* In. Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) Oxford University Press, 2016.
8. **Basu A.** *Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis.* In. Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) Oxford University Press, 2016.
9. Kuntz K, Sculpher S, Krahn M, Meltzer D, **Basu A.** *Reflecting uncertainty in cost-effectiveness analysis.* In. Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) Oxford University Press, 2016.
10. **Basu A,** Ganiats T. *Discounting.* In. Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) Oxford University Press, 2016.

11. Kim DD, **Basu A**, Duffy SQ, Zarkin GA. *The cost-effectiveness of treatments for individuals with alcohol-use disorders: A reference care analysis*. In: Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) 2016.

PUBLICATIONS (letters, editorials, commentaries, blog article)

1. **Basu A**. Cost-effectiveness of olanzapine as a first-line treatment: A comment. *Value in Health* (Letter) 2006; 9(5): 357.
2. **Basu A**, Meltzer D. Modeling comparative effectiveness and the value of research. *Annals of Internal Medicine* (Editorial) 2009; 151: 210-211.
3. **Basu A**. Patient-centered or “central” patient: Raising the veil of ignorance over randomization. *Statistics in Medicine* (Commentary) 2012; 31: 3054-3056.
4. **Basu A**, Jena AB, Goldman DP, Philipson TJ, Dubois R. Response to Epstein’s comment on “Heterogeneity in action..”. *Health Economics* (Commentary) 2014; 23(3): 359 – 373.
5. **Basu A**, Axelsen K, Grabaowski DC, Meltzer DO, Polsky D, Ridley DB, Wiederkehr D, Philipson TJ. Real World Data: Responses to Zito and Doshi. *Medical Care* 2016 54(12):1048-1049.
6. Walton SM, **Basu A**, Mullahy J. Measuring the value of pharmaceuticals in the US health system. *PharmacoEconomics* (Editorial) 2017; 35:1.
7. **Basu A**. Want Drug Regulators To Consider Real-World Evidence? Then Disrupt Their Outdated Regulatory Infrastructure. *Health Affairs* 2018; <https://www.healthaffairs.org/doi/10.1377/hblog20171030.999857/full/>

BOOK REVIEWS

1. **Basu A**. Review of *Bayesian Econometric Methods* by Koop, Poirier and Tobias. *Journal of the American Statistical Association* 2009; 104(487): 1273.

PUBLICATIONS (original peer-reviewed articles)

THEORY & METHODS

Causal Inference

1. **Basu A**, Heckman J, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: An application to treatments of breast cancer patients. York Health Econometrics and Data Group (HEDG) Working Paper 07/07. (with Editorial) *Health Economics* 2007; 16(11): 1133 -1157.
2. Terza JV, **Basu A**, Rathouz PJ. Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. *Journal of Health Economics* 2008; 27(3):531-543.
3. **Basu A**. Estimating decision-relevant comparative effects using instrumental variables. *Statistics in Biosciences* (Special Issue on Comparative Effectiveness Research) 2011; 3(1): 6-27.
4. **Basu A**. Chan KCG. Can we make smart choices between OLS versus Contaminated IV estimators? *Health Economics* 2014; 23(4):462-72.
5. **Basu A**. Person-Centered Treatment (PeT) effects using instrumental variables: An application to evaluating prostate cancer treatments. 2012 *National Bureau of Economic Research Working Paper* No w18056. *Journal of Applied Econometrics* 2014; 29:671-691.
6. **Basu A**. Person-centered treatment (PeT) effects: Individualized treatment effects with instrumental variables. *Stata Journal* 2015; 15(2): 397-410.
7. **Basu A**, Coe NB, Chapman CG. 2SLS vs 2SRI: Appropriate methods for rare outcomes and/or rare exposures. ? *Health Economics* 2018; In Press.

Health Economics

8. Meltzer D, Chung J, **Basu A**. Does competition under Medicare prospective payment selectively reduce expenditures on high-cost patients? *RAND Journal of Economics* 2003; 33(3): 447-468.
9. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. *Journal of Health Economics* 2005; 24(4): 751-773.
10. Huang E, **Basu A**, O'Grady M, Capretta JC. Using clinical information to project federal health care spending. *Health Affairs* 2009; 28(5):w978-w990.
11. **Basu A**. Individualization at the heart of comparative effectiveness research: The time for *i*-CER has come. *Medical Decision Making* 2009. 29(6): N9-N11. [<http://mdm.sagepub.com/cgi/reprint/29/6/NP9>]
12. Meltzer D, **Basu A**, Conti R. The Economics of comparative effectiveness studies: Societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research. *PharmacoEconomics* 2010; 28(10):843-853
13. **Basu A**. Economics of individualization in comparative effectiveness research and a basis for a patient-centered healthcare. 2011 *NBER Working Paper* No. w16900. *Journal of Health Economics* 2011; 30(3): 549-559.
14. **Basu A**, Jena A, Philipson T. Impact of comparative effectiveness research on health and healthcare spending. 2010 *NBER Working Paper* No. w15633. *Journal of Health Economics* 2011; 30(4): 695-706.
15. **Basu A**, Meltzer HY. Tying Comparative Effectiveness Information to Decision Making and the Future of CER Designs: The case for Antipsychotic Drugs. *Journal of Comparative Effectiveness Research* 2012; 1(2): 171-180.
16. **Basu A**, Meltzer D. Private manufacturers' thresholds to invest in comparative effectiveness trials. *PharmacoEconomics* 2012; 30(10): 859-868.
17. **Basu A**. Personalized Medicine in the Context of Comparative Effectiveness Research. *Forum for Health Economics and Policy* 2013; 16(2): 107-120.
18. **Basu A**, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: Role of *passive* personalization in comparative effectiveness research. *Health Economics* (with Discussions) 2014; 23(3): 359 – 373.
19. **Basu A**. Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed. *Expert Review of Pharmacoeconomics & Outcomes Research* 2013; 13(2); 163-165.
20. **Basu A**. Financing Cures in the United States. *Expert Review of Pharmacoeconomics and Outcomes Research* 2015;15(1):1-4.
21. **Basu A**. Welfare implications of learning through solicitation versus diversification in health care. NBER Working paper # 20367. *Journal of Health Economics* 2015; 42: 165-173.
22. **Basu A**, Subedi P, Kamal-Bahl S. Financing a cure for diabetes in a multi-payer environment. *Value in Health* 2016; 19(6):861-868.
23. **Basu A**, Axelsen K, Grabaowski DC, Meltzer DO, Polsky D, Ridley DB, Wiederkehr D, Philipson TJ. Real World Data: Policy issues regarding their access and use. *Medical Care* 2016 54(12):1038-1044.
24. Sanders GD, Neumann PJ, **Basu A**, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-Effectiveness Analyses in Health and Medicine: The Second Panel on Cost-Effectiveness in Health and Medicine. *Journal of the American Medical Association* 2016; 316(10): 1093-1103.
25. **Basu A**, Sullivan SD. Towards a hedonic value framework in health care. *Value in Health* 2017; 20: 261-265.
26. Kim DD, **Basu A**. New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. *Medical Decision Making* 2017; 37(8): 930-941.
27. Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, **Basu A**, Danzon PM. Defining elements of value in health care – A health economics approach: an ISPOR Special Task Force Report [3]. *Value in Health* 2018; 21(2): 131-139.
28. Phelps CE, Lakdawalla DN, **Basu A**, Drummond MF, Towse A, Danzon PM. Approaches to aggregation and decision making – A health making approach: an ISPOR Special Task Force Report [5]. *Value in Health* 2018; 21(2): 146-154.
29. Garrison LP, Neumann PJ, Willke RJ, **Basu A**, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A health economics approach to US value assessment frameworks – Summary and recommendations of the ISPOR Special Task Force Report [7]. *Value in Health* 2018; 21(2): 161-165.
30. Slejko J, **Basu A**, Sullivan SD. Returns to Scientific Publications for Pharmaceutical Products in the U.S. *Health Economics* In Press.
31. **Basu A**, Jones AM, Dias PR. Heterogeneity in the Impact of Type of Schooling on Adult Health and Lifestyle. *Journal of Health Economics* 2018; 57: 1-14.

32. Bennette CS, **Basu A**, Ramsey RD, Helms Z, Bach PB. Health returns to pharmaceutical innovation in the market for oral chemotherapy in response to Insurance coverage expansion. ***American Journal of Health Economics*** In press.

Modeling of Health Care Cost & Utilizations

33. **Basu A**, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? ***Health Economics*** 2004; 13(8): 749-765.
34. **Basu A**, Rathouz P. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. ***Biostatistics*** 2005; 6(1): 93-109.
35. Manning WG, **Basu A**, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes. 2003 NBER Working Paper No. t0293. ***Journal of Health Economics*** 2005; 24(3): 465-488.
36. **Basu A** Extended generalized linear models: Simultaneous estimation of link and variance functions. ***The Stata Journal*** 2005; 5(4): 501-516.
37. **Basu A**, Arondekar BV, Rathouz P. Scale of interest versus scale of estimation: Comparing alternative estimators for the incremental costs of a comorbidity. ***Health Economics*** 2006; 15(10): 1091-1107.
38. **Basu A**, Manning WG. A test for proportional hazards assumption within the class of exponential conditional mean framework. ***Health Services and Outcomes Research Methodology*** 2006; 6(3-4): 81-100.
39. **Basu A**, Manning WG. Issues for the next generation of healthcare costs analyses. ***Medical Care*** 2009; 47(7_Supplement_1):S109-S114.
40. **Basu A**, Manning WG. Estimating life-time or episode cost of illness under censoring. York Health Econometrics and Data Group (HEDG) Working Paper 09/09. ***Health Economics*** 2010; 19(9): 1010-1028.
41. **Basu A**, Polsky D, Manning WG. Estimating treatment effects on healthcare costs under exogeneity: Is there a 'magic bullet'? York Health Econometrics and Data Group (HEDG) Working Paper 08/11; 2008 NBER Working Paper No. w14086. ***Health Services and Outcomes Research Methodology*** 2011; 11:1-26.
42. Borah B, **Basu A**. Highlighting differences between conditional and unconditional quantile regression approaches through an application to assess medication adherence. ***Health Economics*** 2013; 22(9): 1052-1070.
43. Kim DD, **Basu A**. Estimating the medical care costs of obesity in the US: Systematic review, meta-analysis and empirical analysis. ***Value in Health*** 2016; 19: 602-613.
44. Park S, **Basu A**. Alternative evaluation metrics for risk adjustment methods. ***Health Economics*** In Press.

Quality of Life Measurement & Modeling

45. Dale W, **Basu A**, Meltzer D, Elstein A. Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of alternative theories. ***Medical Decision Making*** 2008; 28(1): 102 – 112.
46. **Basu A**, Dale W, Elstein A, Meltzer D. A Linear Index for Predicting Joint Health States Utilities from Single Health States Utilities. ***Health Economics*** 2009; 18(4): 403-419.
47. **Basu A**, Dale William, Elstein A, Meltzer D. A time trade-off method for eliciting partner's quality of life due to patient's health states in prostate cancer. ***Medical Decision Making*** 2010; 30(3): 355-365.
48. Dale W, Bilir SP, Hemmerich J, **Basu A**, Elstein A, Meltzer D. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer. ***Medical Care*** 2011; 49(1): 59-66.
49. Lee J, Rhee K, O'Grady MJ, **Basu A**, Winn A, John P, Meltzer DO, Koleman C, Laffel L, Lawrence J, Tamborlane WV, Wysocki T, Xing D, Huang ES. Health utilities for children and adults with type 1 diabetes. ***Medical Care*** 2011; 49(10): 924-931.
50. **Basu A**, Manca A. Regression estimators for generic health-related quality of life and quality-adjusted life-years. ***Medical Decision Making*** 2012; 32(1):56-69.

Value of Information Analyses

51. **Basu A**, Meltzer D. Value of information on preference heterogeneity and individualized care. ***Medical Decision Making*** 2007; 27(2):112-127.
52. Meltzer D, **Basu A**, Meltzer HY. Comparative effectiveness research for antipsychotic medications: How much research is enough? ***Health Affairs*** 2009; 28(5): w794-w808.

53. **Basu A**, Meltzer D. Quantitative methods for valuing comparative effectiveness information. ***Biopharmaceutical Report***. Fall 2010; 17(2): 2-10.
54. Meltzer D, Hoomans T, Chung JW, **Basu A**. Minimal Modeling Approaches to Value of Information Analysis for Health Research. ***Medical Decision Making*** 2011; 31(6): E1-E22.
55. Hoomans T, Seidenfeld J, **Basu A**, Meltzer, D. Systematizing the Use of Value of Information Analysis in Prioritizing Systematic Reviews. (Prepared by the University of Chicago Medical Center through the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058.) ***AHRQ Publication No. 12-EHC109-EE***. Rockville, MD: Agency for Healthcare Research and Quality. August 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
56. Bennette CS, Ramsey SD, McDermott C, Carlson JJ, **Basu A**, Veenstra DL. Predicting poor accrual in oncology trials: an empirical evaluation of risk factors associated with poor accrual in the National Clinical Trials Network (NCTN) portfolio. ***Journal of the National Cancer Institute***. 2015;108(2): djv324.
57. **Basu A**, Carlson JJ, Veenstra DL. A framework for prioritizing research investments in precision medicine. ***Medical Decision Making*** 2016 36(5): 567-80.
58. Bennette CS, Veenstra DL, **Basu A**, Ramsey SD, Carlson JJ. Development and Evaluation of an approach to using Value of Information Analyses for real-time prioritization decisions within SWOG, a large cancer clinical trials cooperative group. ***Medical Decision Making*** 2016; 36(5): 641-51.
59. Wang W-J, Robertson JC, **Basu A**. Burden of illness and research investments in translational sciences: The case for pharmaceuticals in metastatic cancers. ***Journal of Comparative Effectiveness Research*** 2017; 6(1): 15-24.
60. Dhanda D, Guzauskas G, Carlson J, **Basu A**, Veenstra D. Are evidence standards different for genomic- vs. clinical-based precision medicine? ***Clinical Pharmacology and Therapeutics*** 2017; 102(5):805-814.
61. **Basu A**, Meltzer D. Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events. ***Medical Decision Making*** 2018; 38(4): 427-438.

APPLICATIONS

Comparative Evaluations

62. **Basu A**, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. ***Schizophrenia Research*** 2006; 86(1-3): 99-109.
63. Yin W, **Basu A**, Zhang J, Rabbani A, Meltzer DO, Alexander GC. The impact of the Medicare Part D prescription drug benefit on drug utilization and out-of-pocket expenditures. (with Editorial) ***Annals of Internal Medicine*** 2008; 148: 169-177.
64. **Basu A**, Paltiel DA, Pollack HA. Social costs of robbery and the cost-effectiveness of substance abuse treatment. ***Health Economics*** 2008; 17(8): 926-948.
65. **Basu A**, Yin W, Alexander CG. Impact of Medicare Part D on the prescription utilization of elderly dual-eligible patients. 2008 *NBER Working Paper* No. w14413. ***Health Services Research*** 2009. 45(1): 133-151.
66. Huang E, O'Grady M, **Basu A**, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T. The cost-effectiveness of continuous glucose monitoring in Type 1 diabetes. ***Diabetes Care*** 2010; 33(6): 1269-1274.
67. **Basu A**, Kee RA, Buchanan D, Sadowski LS. Comparative cost analysis of housing and case management program for chronically ill homeless adults compared to usual care. ***Health Services Research*** 2012; 47(1pt2): 523-543.
68. Hillemeier MM, Domino ME, Wells RS, Goyal RK, Kum H-C, Cilenti D, Whitmire JT, **Basu A**. Effects of Maternity Care Coordination on Pregnancy Outcomes: Propensity-Weighted Analyses. ***Maternal and Child Health Journal*** 2014; (In Press)
69. **Basu A**, Gore J. Are elderly patients with clinically localized prostate cancer overtreated? Exploring heterogeneity in survival effects. ***Medical Care*** 2015; 53(1):79-96.
70. Agapova M, Duignan A, Smith A, O'neill Ciaran, **Basu A**. Comparing long-term costs of introducing HPV DNA post-treatment surveillance in national cervical cancer screening in Ireland: a budget impact analysis. ***Expert Review of Pharmacoeconomics & Outcomes Research*** 2015; 15(6): 999-1015.
71. Yeung K, **Basu A**, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-Based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. ***Medical Care*** 2017; 55(2): 191-198.
72. **Basu A**, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic Analysis of the Phase III MENSA Study Evaluating Mepolizumab for Severe Asthma with Eosinophilic Phenotype. ***Expert Review of Pharmacoeconomics & Outcomes Research*** 2017; 17(2): 121 – 131.

73. Yeung K, **Basu A**, Marcum Z, Watkins JB, Sullivan SD. Impact of a value-based formulary in three chronic disease cohorts. *American Journal of Managed Care* In Press.
74. Kauf T, Prabhu V, Medic G, Borse RH, Miller B, Gaultney J, Shen SS, **Basu A**. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. *BMC Infectious Diseases* 2017; In Press.
75. Hillemeier MM, Domino ME, Wells RS Goyal RK, Kum H-C, Cilenti D, Whitmire JT, **Basu A**. Does Maternity Care Coordination Influence Perinatal Health Care Utilization? Evidence from North Carolina. *Health Services Research* 2017; In press.
76. Domino ME, **Basu A**, Hillemeier MM, Wells R, Cilenti D, Goyal RK. Heterogeneous impact of maternity care coordination and selective uptake across health departments. *Health Services Research* 2017; In Press.
77. Prabhu V, Solomkin JS, Medic G, Foo J, Borse RH, Kauf T, Miller B, Shen SS, **Basu A**. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States. *Antimicrobial Resistance & Infection Control* 2017; 20(8): 840-849.
78. **Basu A**, Benson C, Alphas L. Projecting the Potential Impact of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries With Schizophrenia. *Journal of Managed Care & Specialty Pharmacy* 2018; In Press.

Outcomes Research

79. **Basu A**, Tong P, Alexander KS, Dollimore D. Extension of the compartment theory for hindered settling behavior." *S.T.P. Pharma Sciences* 1997; 7(3): 215-222.
80. Tong P, **Basu A**, Alexander KS, Dollimore D. Development of a new theory for hindered settling suspensions. *S.T.P. Pharma Sciences* 1998; 8(4): 241-247.
81. Abdalla I, **Basu A**, Hellman S. An evidence-based analysis of the management of localized prostate cancer. *The Cancer Journal* 2002. Jan-Feb; 8(1): 40-6.
82. Jani AB, **Basu A**, Heinmann R, Hellman, S. Sentinel node versus axillary node dissection for the early stage breast cancer: A comparison using a utility-adjusted NNT (Number Needed to Treat) analysis. *Cancer* 2003; January; 97(2): 359-366.
83. Jani AB, **Basu A**, Abdalla I, Connell PP, Krautz L, Vijayakumar S. The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate or high-risk prostate cancer. *American Journal of Clinical Oncology* 2003; August 26(4):382-385.
84. **Basu A**. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. *Schizophrenia Research* 2004; 71(2-3): 445-462.
85. Dickinson M, **Basu A**. Multilevel modeling and practice-based research. *Annals of Family Medicine* 2005; 3(Supp 1): S52-S60.
86. Lindau ST, **Basu A**, Leitsch SA. Health literacy as a predictor of follow-up after an abnormal pap smear: A prospective study. *Journal of General Internal Medicine* 2006; 21(8): 829 – 834. [PMID: 16881942]
87. **Basu A**, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: A Bayesian meta-analytic approach. *Statistics in Medicine* 2006; 25(17): 2886 - 2910.
88. Huang ES, **Basu A**, Finch M, Frytak J, Manning WG. The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. *Current Medical Research and Opinion* 2007; 23(6): 1423-1430.
89. Alexander GC, Zhang J, **Basu A**. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. *Medical Care* 2008; 46: 394-402.
90. Van Voorhees BW, Paunesku D, Kuwabara SA, **Basu A**, Gollan J, Hankin BL, Melkonian S, Reinecke M. Protective and vulnerability factors predicting new-onset depressive episode in a representative of US adolescents *Journal of Adolescent Health* 2008;42(6):605-16.
91. Van Voorhees BW, Ellis JM, Gollan J, **Basu A**. Predicting future risk of depressive episode in adolescents: the Chicago Adolescent Depression Risk Assessment (CADRA). *Annals of Family Medicine* 2008 Nov-Dec;6(6):503-511.
92. Huang E, **Basu A**, O'Grady M, Capretta J. Projecting the future diabetes population size and related costs for the United States. *Diabetes Care* 2009; 32:2225-2229.
93. Shah LM, King AC, **Basu A**, Krishnan JA, Borden WB, Meltzer D, Arora V. Effect of clinician advice and patient preparedness to quit on subsequent quit attempts in hospitalized smokers . *Journal of Hospital Medicine* 2010. 5(1): 26-32.

94. **Basu A.** Forecasting distribution of body-mass index categories in United States: Is there more room for growth? ***Medical Decision Making*** 2010; 30(3): E1-E11.
95. Arora V, Fish M, **Basu A**, Olson J, Plein C, Suresh K, Sachs G, Meltzer DO. Relationship Between Quality of Care for Hospitalized Vulnerable Elders and Post-Discharge Mortality. ***Journal of the American Geriatrics Society*** 2010; 58(9): 1642-8.
96. Helfand M, Tunis S, Whitlock EP, Pauker SG, **Basu A**, Chilingirian J, Harrell FE, Meltzer DO, Montori VM, Shepard DS, Kent DM and the Methods Work Group of the National CTSA Strategic Goal Committee on Comparative Effectiveness Research. A CTSA agenda to advance methods for comparative effectiveness research. ***Clinical and Translational Science*** 2011; 4(3): 188-198.
97. Ruedy KJ, Tamborlane WV; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Basu A**). The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence. ***Journal of Cardiovascular Translational Research***. 2012 Aug;5(4):380-7.
98. Goldberger JJ, **Basu A**, Buxton AE, Cain M, Chen P-S, Constantini O, Exner DV, Lloyd-Jones D, Kadish AH, Lee B, Moss A, Meyerberg R, Olgin J, Passman R, Rosenbaum D, Stevenson W, Tomaselli G, Zareba W, Zipes DP, Zoloth L. Risk Stratification for Sudden Cardiac Death: A Plan for the Future. ***Circulation*** 2014; 129:516-526.
99. Shepherd-Banigan M, Bell JF, **Basu A**, Booth-LaForce C, Harris JR. Workplace stress and working from home influence depressive symptoms among employed women with young children. ***International Journal of Behavioral Medicine***. 2016; 23(1): 102-11.
100. Shepherd-Banigan M, Bell JF, **Basu A**, Booth-LaForce C, Harris JR. Mothers' employment attributes and use of preventive child health services. ***Medical Care Research and Review*** 2016 In press
101. Sabbatini A, Kocher KE, **Basu A**, Hsia RY. In-Hospital Outcomes and Costs Among Patients Hospitalized During a Return Visit to the Emergency Department. ***Journal of the American Medical Association*** 2016; 315(7):663-671.
102. Wright DR, Lozano P, Dawson-Hahn E, Christakis DA, Haaland W, **Basu A**. Parental Predictions and Perceptions Regarding Long-Term Childhood Obesity-Related Health Risks. ***Academic Pediatrics*** 2016; 16(5): 475-481.
103. Elliott KE, Klein JA, **Basu A**, Sabbatini AK. Using Transitional Care Clinics to Improve Follow-up & Primary Care linkage for Patients Discharged from the Emergency Department. ***American Journal of Emergency Medicine*** 2016; 34(7): 1230-5.
104. Simianu VV, **Basu A**, Alfonso-Cristancho R, Thirlby RC, Flaxman AD, Flum DR. Assessing surgeon behavior change after anastomotic leak in colorectal surgery. ***Journal of Surgery Research*** 2016; 205(2): 378-83.
105. Yeung K, Suh K, **Basu A**, Garrison LP, Bansal A, Carlson JJ. Paying for cures: How can we afford it? Managed care pharmacy stakeholder perceptions of policy options to address affordability of prescription drugs. ***Journal of Managed Care and Specialty Pharmacy*** 2017; 23(10): 1084-90.
106. Brennan MB, Huang ES, Lobo JM, Kang H, Guihan M, **Basu A**, Sohn M-W. Longitudinal trends and predictors of statin use among patients with diabetes. ***Journal of Diabetes and its Complications*** 2018 Jan;32(1):27-33.
107. Kim DD, Aterburn DE, Sullivan SD, **Basu A**. Association between the publication of clinical evidence and the use of bariatric surgery. ***Obesity Surgery*** 2018; In Press.
108. Kim DD, Aterburn DE, Sullivan SD, **Basu A**. Economic Value of Greater Access to Bariatric Procedures for Patients with Severe Obesity and Diabetes. ***Medical Care***. 2018 In Press.

PUBLICATIONS (under review)

109. Domino ME, **Basu A**, Hillemeier M, Wells R, Clienti D, Goyal R. Maternal care coordination: do health departments target clients most likely to benefit?
110. Shephard-Banigan M, **Basu A**, Bell JF, Booth-Laforce C, Harris JR. Does maternal income in childhood affect adolescent health and behavioral outcomes?
111. **Basu A**, Sohn M-W, Bartle B, Chan KCG, Guihan M, Cooper JM, Huang EH. Development and validation of the real-world progression in diabetes (RAPIDS) model.
112. Li M, Banks J, Branch K, Veenstra D, Carlson JJ, Probstfield J, **Basu A**. Towards priority setting for clinical trial investments: Do we measure endpoints that we can value – The case for heart failure clinical trials.
113. Bansal A, **Basu A**. Cure fraction modeling and optimal follow-up.
114. Ellyson A, **Basu A**. The new prescription drug paradox: Pipeline pressure and rising prices.
115. **Basu A**, Prabhu V, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, Hanson ME, Marcella S. Bezlotoxumab is Associated with a Reduction in Cumulative Inpatient Days: Analysis of the Hospitalization Data from the MODIFY I and II Clinical Trials.

116. Park S, **Basu A**, Coe NB, Khalil F. Service-level selection: Strategic risk selection in Medicare Advantage in response to risk adjustment.
117. Banerjee S, **Basu A**. Estimating endogenous treatment effects using latent factor models.
118. Karimi SM, **Basu A**. Development effects of prenatal exposure to Ramadan
119. Yeung K, **Basu A**, Hansen RN, Sullivan SD. Price elasticities of pharmaceuticals in a value-based formulary setting.

UNPUBLISHED PAPERS

120. **Basu A**, Thariani R. Jointness Box (JB)-Area: A novel metric to contemplate potential value of individualized care from traditional trials data.
121. Meltzer D, **Basu A**. Can we better inform medical research spending decisions? An application of value of research techniques to muscular dystrophy.
122. **Basu A**. Flexible models for fractional response variables and outcomes with truncated supports.
123. Meltzer D, **Basu A**, Egleston B, Zhang H. Effects of quality of life on the cost effectiveness analysis of prostate cancer.
124. **Basu A**, Coe N, Grembowski D, Kessler K. Political Polarization, Anticipated Health Insurance Uptake and Individual Mandate: A view from the Washington State. NBER Working paper # 20655.